[ad_1]
The study, which has yet to be reviewed and conducted by scientists at the University of Texas in the United States in cooperation with “Pfizer”, indicated that the American company’s vaccine was found to be effective in neutralizing the coronavirus mutation, known as “N501Y”.
“Reuters” quoted Pfizer chief viral vaccine scientist Phil Dormitzer as saying that the mutation “could be responsible for the increased transmissibility of the disease, and there were concerns that it could cause the virus to escape antibodies. produced by the vaccine “.
Dormitzer added: “It is encouraging that the vaccine appears to be effective against the mutation, in addition to the 15 other mutations Pfizer has been tested against.”
“We have now tested 16 different mutations, and none of them had a significant effect. This is the good news,” he added.
And scientists came to their results after conducting a study of blood taken from people who had received the vaccine, but its results are limited because it does not take into account the full set of mutations present in one. new variants of the rapidly spreading virus.
Researchers plan to run similar tests to see if the vaccine is effective against other mutations found in variants in the UK and South Africa, and they hope to have more data within a few weeks.
Scientists have expressed concern that the vaccines introduced may not be able to protect against new mutations, especially those that have appeared in South Africa.
Commenting on this, Simon Clark, assistant professor of cell microbiology at the University of Reading, said that while the two variants have some new features in common, the type found in South Africa “contains a number of additional mutations” which include modifications. More understandable.
It should be noted that the “Pfizer-Biontech” vaccine, which was developed by “Moderna”, is quickly adjustable to treat any new mutation which could occur in the virus if necessary.
[ad_2]
Source link
